ew Oral Anticoagulants (NOAC) Study: Investigation of laboratory tests an development of a gold standard test for monitoring dabigatran and rivaroxaban therapy

• Conditions: 10007521; 10014523; thrombosis; blood clot

• Registration Number: NL-OMON39575
• Lead Sponsor: Catharina-ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

Patients using dabigatran (CZE hospital) or rivaroxaban (MMC hospital) in a profylactic dose

Exclusion Criteria

renal failure (GFR <30 ml/min), use of antiplatelet agents, previous malignancy, use of other oral anticoagulants (cumarins), age <18 years

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Several clotting tests are compared with each other and the gold standard to<br /><br>select the best test.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To determine target values for dabigatran concentrations with different dosage<br /><br>regimes</p><br>